Literature DB >> 34912990

Comparison of percutaneous MitraClip versus mitral valve surgery for severe mitral regurgitation: a meta-analysis: Mitraclip and mitral valve surgery meta-analysis.

Tom Kai Ming Wang1,2, Andrew Chatfield1, Michael Tzu Min Wang1, Peter Ruygrok1.   

Abstract

AIMS: Mitral valve surgery (MVS) is the gold-standard treatment for severe symptomatic mitral regurgitation. Percutaneous mitral valve interventions such as the MitraClip procedure offer another dimension to its management particularly in high-risk patients. We meta-analysed the outcomes of MitraClip and MVS. METHODS AND
RESULTS: PubMed, MEDLINE, Embase, Cochrane and Scopus from 1980/01-2019/06 were searched for eligible studies. Data were extracted and pooled using random-effects models. After screening 959 studies and reviewing 21 full-text articles, nine studies totalling 640 MitraClip and 531 MVS (91% valve repair) procedures were included in the meta-analysis. MitraClip patients were older, with a higher prevalence of previous cardiac surgery, coronary disease and a higher EuroSCORE (all p<0.05) than MVS patients. Pooled operative mortality was similar for MitraClip, 3%, versus MVS, 5%, odds ratio (OR): 0.58, 95%, CI: 0.28-1.19, as well as at 1 year mortality, OR: 1.09, CI: 0.71-1.68 and 3-year mortality, OR: 1.08, CI: 0.72-0.163. MitraClip patients had higher rates of early and late significant mitral regurgitation (MR) and more cardiovascular readmissions, while MVS had higher rates of in-hospital bleeding and pacemaker implantation (all p<0.05).
CONCLUSIONS: MitraClip patients had a higher baseline risk than MVS, but there were no significant differences in short- and long-term mortality. MitraClip patients had higher rates of cardiovascular admissions and significant MR post-operatively, while MVS patients had more procedural complications.

Entities:  

Year:  2020        PMID: 34912990      PMCID: PMC8525719          DOI: 10.4244/AIJ-D-19-00036

Source DB:  PubMed          Journal:  AsiaIntervention        ISSN: 2426-3958


  39 in total

1.  Prevalence and correlates of mitral regurgitation in a population-based sample (the Strong Heart Study).

Authors:  E C Jones; R B Devereux; M J Roman; J E Liu; D Fishman; E T Lee; T K Welty; R R Fabsitz; B V Howard
Journal:  Am J Cardiol       Date:  2001-02-01       Impact factor: 2.778

2.  Minimally invasive mitral valve repair for functional mitral regurgitation in severe heart failure: MitraClip versus minimally invasive surgical approach.

Authors:  Tomas Ondrus; Jozef Bartunek; Marc Vanderheyden; Bernard Stockman; Martin Kotrc; Frank Van Praet; Guy Van Camp; Patrick Lecomte; Yujing Mo; Martin Penicka
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-06-29

3.  Impact of residual mitral regurgitation after MitraClip implantation.

Authors:  Hidehiro Kaneko; Michael Neuss; Jens Weissenborn; Christian Butter
Journal:  Int J Cardiol       Date:  2016-10-24       Impact factor: 4.164

4.  2017 ESC/EACTS Guidelines for the management of valvular heart disease.

Authors:  Helmut Baumgartner; Volkmar Falk; Jeroen J Bax; Michele De Bonis; Christian Hamm; Per Johan Holm; Bernard Iung; Patrizio Lancellotti; Emmanuel Lansac; Daniel Rodriguez Muñoz; Raphael Rosenhek; Johan Sjögren; Pilar Tornos Mas; Alec Vahanian; Thomas Walther; Olaf Wendler; Stephan Windecker; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2017-09-21       Impact factor: 29.983

Review 5.  Proportionate and Disproportionate Functional Mitral Regurgitation: A New Conceptual Framework That Reconciles the Results of the MITRA-FR and COAPT Trials.

Authors:  Paul A Grayburn; Anna Sannino; Milton Packer
Journal:  JACC Cardiovasc Imaging       Date:  2018-12-12

6.  Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment.

Authors:  F Grigioni; M Enriquez-Sarano; K J Zehr; K R Bailey; A J Tajik
Journal:  Circulation       Date:  2001-04-03       Impact factor: 29.690

7.  Mitraclip therapy and surgical mitral repair in patients with moderate to severe left ventricular failure causing functional mitral regurgitation: a single-centre experience.

Authors:  Maurizio Taramasso; Paolo Denti; Nicola Buzzatti; Michele De Bonis; Giovanni La Canna; Antonio Colombo; Ottavio Alfieri; Francesco Maisano
Journal:  Eur J Cardiothorac Surg       Date:  2012-09-07       Impact factor: 4.191

8.  What is a "good" result after transcatheter mitral repair? Impact of 2+ residual mitral regurgitation.

Authors:  Nicola Buzzatti; Michele De Bonis; Paolo Denti; Fabio Barili; Davide Schiavi; Giovanna Di Giannuario; Giovanni La Canna; Ottavio Alfieri
Journal:  J Thorac Cardiovasc Surg       Date:  2015-10-01       Impact factor: 5.209

9.  Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.

Authors:  Martin B Leon; Craig R Smith; Michael J Mack; Raj R Makkar; Lars G Svensson; Susheel K Kodali; Vinod H Thourani; E Murat Tuzcu; D Craig Miller; Howard C Herrmann; Darshan Doshi; David J Cohen; Augusto D Pichard; Samir Kapadia; Todd Dewey; Vasilis Babaliaros; Wilson Y Szeto; Mathew R Williams; Dean Kereiakes; Alan Zajarias; Kevin L Greason; Brian K Whisenant; Robert W Hodson; Jeffrey W Moses; Alfredo Trento; David L Brown; William F Fearon; Philippe Pibarot; Rebecca T Hahn; Wael A Jaber; William N Anderson; Maria C Alu; John G Webb
Journal:  N Engl J Med       Date:  2016-04-02       Impact factor: 91.245

10.  Mitral-valve repair versus replacement for severe ischemic mitral regurgitation.

Authors:  Michael A Acker; Michael K Parides; Louis P Perrault; Alan J Moskowitz; Annetine C Gelijns; Pierre Voisine; Peter K Smith; Judy W Hung; Eugene H Blackstone; John D Puskas; Michael Argenziano; James S Gammie; Michael Mack; Deborah D Ascheim; Emilia Bagiella; Ellen G Moquete; T Bruce Ferguson; Keith A Horvath; Nancy L Geller; Marissa A Miller; Y Joseph Woo; David A D'Alessandro; Gorav Ailawadi; Francois Dagenais; Timothy J Gardner; Patrick T O'Gara; Robert E Michler; Irving L Kron
Journal:  N Engl J Med       Date:  2013-11-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.